- Home
- BBIO vs VRNA Comparison
BBIO vs VRNA Comparison
Compare BBIO & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- VRNA
- Stock Information
- Founded
- BBIO 2015
- VRNA 2005
- Country
- BBIO United States
- VRNA United Kingdom
- Employees
- BBIO N/A
- VRNA N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- BBIO Health Care
- VRNA Health Care
- Exchange
- BBIO Nasdaq
- VRNA Nasdaq
- Market Cap
- BBIO 9.4B
- VRNA 8.3B
- IPO Year
- BBIO 2019
- VRNA 2017
- Fundamental
- Price
- BBIO $53.33
- VRNA $106.26
- Analyst Decision
- BBIO Strong Buy
- VRNA Buy
- Analyst Count
- BBIO 16
- VRNA 11
- Target Price
- BBIO $64.44
- VRNA $114.10
- AVG Volume (30 Days)
- BBIO 2.1M
- VRNA 1.4M
- Earning Date
- BBIO 11-11-2025
- VRNA 11-03-2025
- Dividend Yield
- BBIO N/A
- VRNA N/A
- EPS Growth
- BBIO N/A
- VRNA N/A
- EPS
- BBIO N/A
- VRNA N/A
- Revenue
- BBIO $235,812,000.00
- VRNA $221,673,000.00
- Revenue This Year
- BBIO $115.97
- VRNA $896.59
- Revenue Next Year
- BBIO $65.50
- VRNA $77.56
- P/E Ratio
- BBIO N/A
- VRNA N/A
- Revenue Growth
- BBIO 7.62
- VRNA N/A
- 52 Week Low
- BBIO $21.72
- VRNA $27.54
- 52 Week High
- BBIO $54.60
- VRNA $106.45
- Technical
- Relative Strength Index (RSI)
- BBIO 60.01
- VRNA 67.69
- Support Level
- BBIO $49.94
- VRNA $106.18
- Resistance Level
- BBIO $54.29
- VRNA $106.42
- Average True Range (ATR)
- BBIO 2.06
- VRNA 0.19
- MACD
- BBIO -0.18
- VRNA -0.17
- Stochastic Oscillator
- BBIO 73.81
- VRNA 74.32
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.